Genovis AB
STO:GENO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
22.7
53.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GENO stock under the Base Case scenario is 31.99 SEK. Compared to the current market price of 22.85 SEK, Genovis AB is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Genovis AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GENO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Genovis AB
Balance Sheet Decomposition
Genovis AB
Current Assets | 180m |
Cash & Short-Term Investments | 135.8m |
Other Current Assets | 44.2m |
Non-Current Assets | 123.4m |
Long-Term Investments | 90k |
PP&E | 91.4m |
Intangibles | 19.4m |
Other Non-Current Assets | 12.5m |
Current Liabilities | 18.8m |
Other Current Liabilities | 18.8m |
Non-Current Liabilities | 77m |
Long-Term Debt | 75.1m |
Other Non-Current Liabilities | 2m |
Earnings Waterfall
Genovis AB
Revenue
|
127m
SEK
|
Cost of Revenue
|
-45.2m
SEK
|
Gross Profit
|
81.8m
SEK
|
Operating Expenses
|
-58.6m
SEK
|
Operating Income
|
23.2m
SEK
|
Other Expenses
|
-5.9m
SEK
|
Net Income
|
17.3m
SEK
|
Free Cash Flow Analysis
Genovis AB
SEK | |
Free Cash Flow | SEK |
GENO Profitability Score
Profitability Due Diligence
Genovis AB's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Genovis AB's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
GENO Solvency Score
Solvency Due Diligence
Genovis AB's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Genovis AB's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GENO Price Targets Summary
Genovis AB
According to Wall Street analysts, the average 1-year price target for GENO is 43.86 SEK with a low forecast of 34.34 SEK and a high forecast of 54.6 SEK.
Shareholder Yield
Current shareholder yield for GENO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
GENO Price
Genovis AB
Average Annual Return | 33.42% |
Standard Deviation of Annual Returns | 65.21% |
Max Drawdown | -74% |
Market Capitalization | 1.5B SEK |
Shares Outstanding | 65 465 714 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Contact
IPO
Employees
Officers
The intrinsic value of one GENO stock under the Base Case scenario is 31.99 SEK.
Compared to the current market price of 22.85 SEK, Genovis AB is Undervalued by 29%.